CDS tools have been shown to reduce clinician workloads as well as provide for efficient data review and enhanced clinical documentation. Tumor board teams gain the opportunity to spend more time with patients and personalize healthcare.1
portfolio selected publications
Hammer, R. D., et al., 2020. JCO Clinical Cancer Informatics, 4, pp.757-768.
Findings in this publication suggest oncology care teams can benefit from improved workflow and efficiency.
Hammer, R. D., et al., 2021. Health and Technology, pp.1-9.
The result of a multi-year research collaboration with the University of Missouri demonstrated how digital tumor board solutions standardized case preparation and reduced case discussion postponement.
Hammer, R. D. and Prime, M.S., 2020. Health Informatics Journal, 26(3), pp.2213-2221.
The University of Missouri School of Medicine and Roche co-developed a digital solution.
Krupinski, E. A., et al., 2018. Journal of pathology informatics, 9.
A pilot of Clinical Hub for Tumor Boards* showed reduced meeting preparation time and improved user satisfaction.
Stephanie J. Yaung, Ph.D. 2020. JMD Journal, Vol. 22, No. 11
The accuracy level of a cloud-based CE-IVD software that aids in interpreting clinically relevant variants detected in somatic oncology next-generation sequencing tests.
Guo, C., et al., 2020. npj Digital Medicine, 3(1), pp.1-14.
This study shares innovative and pragmatic approaches to evolve traditional evidence generation.
Gardner C., et al. Presented at ASCO 2020.
Simulated lung cancer multidisciplinary team meetings tested Clinical Hub for Tumor Boards*
Guo, C., et al. JNCCN 18(3.5), pp.BIO20-026. Presented at NCCN2020.
Preliminary evaluation of Guidelines app showed a decrease in steps to access clinical practice guidelines.
Perakis SO, Weber S, Zhou Q, et al. Presented at ESMO2020.
An in-depth evaluation of a cell-free DNA from patients with metastatic breast, colorectal or non-small cell lung cancer.
John A., et al. DOI: https://doi.org/10.6004/jnccn.2019.7441. Presented at 2020 NCCN Annual Meeting.
Adherence to biomarker testing guidelines may be associated with longer survival in patients with lung cancer.
References & notes
*navify Tumor Board is now a part of navify Clinical Hub, and will be referenced as navify Clinical Hub for Tumor Boards moving forward. For more information, visit navify Clinical Hub for Tumor Boards product page link.
Find us
Roche Information Solutions
Roche Molecular Systems, Inc.
2881 Scott Blvd
Santa Clara, CA 95050
